{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T08:41:36Z","timestamp":1788597696446,"version":"build-2803163510"},"reference-count":22,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2022,9,1]]},"abstract":"<jats:sec id=\"ab-eoi220045-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Taxane-based chemotherapy agents, such as docetaxel and paclitaxel, are used for treating a wide range of cancers. Although much has been published on adverse events related to taxanes, data on ocular outcomes with these very important drugs are scant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi220045-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To quantify the risk of 3 mutually exclusive ocular adverse events of epiphora, cystoid macular edema (CME), and optic neuropathy with taxane-based chemotherapy agents by undertaking a large pharmacoepidemiologic study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi220045-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This retrospective cohort study design used a private health-claims database from the US that captures health information of more than 150 million enrollees. The study team created a cohort of new users of women with cancer who were taking taxane-based chemotherapy (docetaxel or paclitaxel) and new users of tamoxifen as controls. Study members were observed to the first incidence of each of the 3 mutually exclusive outcomes. An analysis of taxane-only users was also undertaken.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi220045-7\">\n                    <jats:title>Exposure<\/jats:title>\n                    <jats:p>Tamoxifen (unexposed) and taxanes (ie, paclitaxel and docetaxel) as the exposed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi220045-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>\n                      First diagnosis of (1) epiphora, (2) cystoid macular edema (CME), or (3) optic neuropathy ascertained using\n                      <jats:italic>International Statistical Classification of Diseases and Related Health Problems, Ninth Revision<\/jats:italic>\n                      or\n                      <jats:italic>International Statistical Classification of Diseases and Related Health Problems, Tenth Revision<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi220045-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 18\u202f219 users in the epiphora analysis and optic neuropathy analysis, there were 1824 taxane users (paclitaxel and docetaxel) (age, mean [SD], 62.1 [12.7] years) and 16\u202f395 tamoxifen users (age, mean [SD], 54.6 [12.8] years), respectively. The crude hazard ratio (HR) for epiphora was 5.55 (95% CI, 2.99-10.29) and adjusted HR was 5.15 (95% CI, 2.79-9.54). For optic neuropathy, the crude HR was 4.43 (95% CI, 1.10-17.82) and the adjusted HR was 4.44 (95% CI, 1.04-18.87). Among the 18\u202f433 users in the CME analysis, there were 1909 taxane users (paclitaxel and docetaxel) (age, mean [SD], 62.5 years) and 16\u202f524 tamoxifen users (age, mean [SD], 54.6 years). The crude HR for CME comparing taxane users with tamoxifen users was 1.37 (95% CI, 0.72-2.60) and adjusted HR was 1.33 (95% CI, 0.70-2.53). The HRs for epiphora and CME in the taxane cohort during the time of exposure compared with the period prior to use of the drugs were 2.86 (95% CI, 1.11-7.39) and 2.27 (95% CI, 0.68-7.54), respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi220045-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In a cohort of women who were using taxane chemotherapy agents, there was an association with elevated risk for epiphora, CME, and optic neuropathy. Ophthalmologists and oncologists should be aware of these adverse events in women with breast cancer who receive these drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2022.3026","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T12:03:16Z","timestamp":1660910596000},"page":"880","source":"Crossref","is-referenced-by-count":24,"title":["Risk of Ocular Adverse Events With Taxane-Based Chemotherapy"],"prefix":"10.1001","volume":"140","author":[{"given":"Mohit","family":"Sodhi","sequence":"first","affiliation":[{"name":"Collaboration for Epidemiology of Ocular Diseases, Department of Ophthalmology and Visual Sciences, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia N.","family":"Yeung","sequence":"additional","affiliation":[{"name":"Collaboration for Epidemiology of Ocular Diseases, Department of Ophthalmology and Visual Sciences, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Maberley","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Mikelberg","sequence":"additional","affiliation":[{"name":"Collaboration for Epidemiology of Ocular Diseases, Department of Ophthalmology and Visual Sciences, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahyar","family":"Etminan","sequence":"additional","affiliation":[{"name":"Collaboration for Epidemiology of Ocular Diseases, Department of Ophthalmology and Visual Sciences, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Department of Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"eoi220045r2","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1186\/1756-0500-7-322","article-title":"Epiphora in lung cancer patients receiving docetaxel: a case series.","volume":"7","author":"Yamagishi","year":"2014","journal-title":"BMC Res Notes"},{"issue":"6","key":"eoi220045r3","first-page":"737","article-title":"[A retrospective analysis of epiphora due to docetaxel].","volume":"43","author":"Noguchi","year":"2016","journal-title":"Gan To Kagaku Ryoho"},{"issue":"11","key":"eoi220045r4","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1248\/bpb.b18-00444","article-title":"Risk factors for eye disorders caused by paclitaxel: a retrospective study.","volume":"41","author":"Noguchi","year":"2018","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"eoi220045r5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2174\/1574886313666180828163016","article-title":"Taxane induced cystoid macular edema: case report and integrated pathogenic theory.","volume":"14","author":"Kanakis","year":"2019","journal-title":"Curr Drug Saf"},{"issue":"2","key":"eoi220045r6","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1159\/000477897","article-title":"Cystoid macular edema during treatment with paclitaxel and bevacizumab in a patient with metastatic breast cancer: a case report and literature review.","volume":"10","author":"Yokoe","year":"2017","journal-title":"Case Rep Oncol"},{"issue":"24","key":"eoi220045r7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1471-2415-14-18","article-title":"Toxic optic neuropathy in the setting of docetaxel chemotherapy: a case report.","author":"Moloney","year":"2014","journal-title":"BMC Ophthalmol"},{"key":"eoi220045r8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1471-2415-15-6","article-title":"Impact of epiphora on vision-related quality of life.","volume":"15","author":"Shin","year":"2015","journal-title":"BMC Ophthalmol"},{"issue":"12","key":"eoi220045r9","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1038\/eye.2017.120","article-title":"Assessment of patient-reported outcome and quality of life improvement following surgery for epiphora.","volume":"31","author":"Sipkova","year":"2017","journal-title":"Eye (Lond)"},{"issue":"3","key":"eoi220045r13","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1159\/000370144","article-title":"Bilateral macular edema in a patient treated with tamoxifen: a case report and review of the literature.","volume":"5","author":"Zafeiropoulos","year":"2014","journal-title":"Case Rep Ophthalmol"},{"issue":"1","key":"eoi220045r14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1046\/j.1442-9071.2004.00769.x","article-title":"Tamoxifen optic neuropathy.","volume":"32","author":"Colley","year":"2004","journal-title":"Clin Exp Ophthalmol"},{"issue":"12","key":"eoi220045r15","first-page":"1751","article-title":"Etiology, diagnosis, management and outcomes of epiphora referrals to an oculoplastic practice.","volume":"9","author":"Shen","year":"2016","journal-title":"Int J Ophthalmol"},{"issue":"4","key":"eoi220045r16","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1136\/bjo.76.4.221","article-title":"Cystoid macular oedema following cataract extraction in patients with diabetes.","volume":"76","author":"Pollack","year":"1992","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"eoi220045r17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0247126","article-title":"Risk factors and visual outcome of Non-Arteritic Ischemic Optic Neuropathy (NAION): experience of a tertiary center in Kuwait.","volume":"16","author":"Behbehani","year":"2021","journal-title":"PLoS One"},{"key":"eoi220045r18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ics.2004.11.065","article-title":"Visual electrophysiological evaluation in paclitaxel-treated patients. pathophysiological mechanisms involved in retinal and optic nerve dysfunctions.","volume":"1278","author":"Scaioli","year":"2005","journal-title":"Int Congr Ser"},{"issue":"2","key":"eoi220045r19","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3390\/toxics3020152","article-title":"Taxane-induced peripheral neurotoxicity.","volume":"3","author":"Velasco","year":"2015","journal-title":"Toxics"},{"issue":"3","key":"eoi220045r20","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy.","volume":"98","author":"Esmaeli","year":"2003","journal-title":"Cancer"},{"issue":"2","key":"eoi220045r21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3892\/mco.2017.1296","article-title":"Cystoid macular edema secondary to paclitaxel therapy for ovarian cancer: a case report.","volume":"7","author":"Bassi","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"eoi220045r1","unstructured":"Science Direct. Taxanes. Accessed January 10, 2022. https:\/\/www.sciencedirect.com\/topics\/neuroscience\/taxanes"},{"key":"eoi220045r10","unstructured":"Breast Cancer Research Foundation. Breast Cancer Statistics and Resources. Accessed January 20, 2022. https:\/\/www.bcrf.org\/breast-cancer-statistics-and-resources\/?utm_source=google&utm_medium=cpc&gclid=CjwKCAiA866PBhAYEiwANkIneB2vlqrP3bm2PPuVWmyUgDxYgjhs4YYtHQJrhKNatnHVPaNh8hmhPRoCwVAQAvD_BwE"},{"key":"eoi220045r11","unstructured":"American Society of Clinical Oncology. Breast cancer statistics. Accessed January 22, 2022. https:\/\/www.cancer.net\/cancer-types\/breast-cancer\/statistics"},{"key":"eoi220045r12","unstructured":"IMS Health. IQVIA PharMetics Plus fact sheet. Accessed January 22, 2022. https:\/\/www.greygreenmedia.com\/app\/uploads\/sites\/2\/2020\/09\/IQVIA-PharMetrics-Plus-US-Fact-Sheet.pdf."},{"key":"eoi220045r22","unstructured":"Data Bridge Market Research. Global taxane market\u2014industry trends and forecast to 2029. Accessed January 22, 2022. https:\/\/www.databridgemarketresearch.com\/reports\/global-taxane-market"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2795314\/jamaophthalmology_sodhi_2022_oi_220045_1663178033.63655.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T11:03:51Z","timestamp":1663239831000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2795314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2022.3026","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.02.15.22270863","asserted-by":"object"}]},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,1]]}}}